Voglio sapere a riguardo di…

35336

Federal Register / Vol. 86, No. 125 / Friday, July 2, 2021 / Notices
General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 202
2052737. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commissions electronic docket information system EDIS at https
edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov.
General information concerning the Commission may also be obtained by accessing its internet server at https
www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commissions TDD
terminal, telephone 202 2051810.
The Commission instituted the present investigation on February 12, 2021, based on a complaint and supplement thereto filed by Samsung Electronics Co., Ltd. of Gyeonggi-do, Korea and Samsung Electronics America, Inc. of Ridgefield Park, New Jersey collectively, Complainants. 85 FR
937071 Feb. 12, 2021. The complaint, as supplemented, alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon the importation, sale for importation, and sale in the United States after importation of certain wireless communications equipment and components thereof by reason of infringement of certain claims of U.S.
Patent No. 9,041,074; U.S. Patent No.
9,521,616; U.S. Patent No. 9,736,772;
and U.S. Patent No. 10,797,405. Id. at 9371. The complaint further alleged that an industry in the United States exists or is in the process of being established, as required by section 337. Id. The notice of investigation named Ericsson AB of Stockholm, Sweden, and Telefonaktiebolaget LM Ericsson of Stockholm, Sweden, and Ericsson Inc., of Plano, Texas. Id.
On May 14, 2021, the parties filed a joint motion to terminate the investigation based on settlement. The parties represent that there are no other agreements, written or oral, expressed or implied between Samsung and Ericsson concerning the subject matter of the investigation. See ID at 2.
On June 10, 2021, the presiding administrative law judge issued Order No. 9, granting the joint motion to terminate the investigation. The ID finds that the motion complies with the requirements of Commission Rule 210.2119 CFR 210.21 and there will not be a negative impact on the public interest. No party filed a petition for review of the ID.

lotter on DSK11XQN23PROD with NOTICES1

SUPPLEMENTARY INFORMATION:

VerDate Sep<11>2014

17:12 Jul 01, 2021

Jkt 253001

The Commission has determined not to review this ID. The investigation is terminated.
The Commission vote for this determination took place on June 28, 2021.
The authority for the Commissions determination is contained in Section 337 of the Tariff Act of 1930, as amended 19 U.S.C. 1337, and in part 210 of the Commissions Rules of Practice and Procedure 19 CFR part 210.
By order of the Commission.
Issued: June 28, 2021.
Lisa Barton, Secretary to the Commission.
FR Doc. 202114149 Filed 7121; 8:45 am BILLING CODE 702002P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration Spring Valley Family Pharmacy;
Decision and Order On April 12, 2021, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration hereinafter, Government, issued an Order to Show Cause hereinafter, OSC to Spring Valley Family Pharmacy hereinafter, Registrant of Gallipolis, Ohio. OSC, at 1. The OSC proposed the revocation of Registrants Certificate of Registration hereinafter, registration No.
FS7068249. Id. It alleged that Registrant currently lacks state authority to handle controlled substances. Id.
citing 21 U.S.C. 824a3.
Specifically, the OSC alleged that on or about October 2, 2020, Registrant permanently and voluntarily surrendered its Ohio state pharmacy license to the State of Ohio Board of Pharmacy with the surrender effective on October 5, 2020. Id. at 2. According to the OSC, Registrant permanently and voluntarily surrendered its Ohio state pharmacy license after its owner and primary operator, Brandon OCallaghan, permanently and voluntarily surrendered his state pharmacist license after testing positive for controlled substances in violation of a Board Order. Id. The OSC concluded that because Registrant is currently without authority to handle controlled substances in Ohio, the state in which Registrant is registered with DEA. . . .
DEA must revoke Registrants registration. . . . Id.
The OSC notified Registrant of the right to request a hearing on the allegations or to submit a written
PO 00000

Frm 00078

Fmt 4703

Sfmt 4703

statement, while waiving the right to a hearing, the procedures for electing each option, and the consequences for failing to elect either option. Id. at 23 citing 21 CFR 1301.43. The OSC also notified Registrant of the opportunity to submit a corrective action plan. Id. at 3 citing 21 U.S.C. 824c2C.
Adequacy of Service In a Declaration dated June 8, 2021, a Diversion Investigator hereinafter, the DI assigned to the Charleston District Office, Louisville Field Division, stated that she and a Tactical Diversion Squad Group Supervisor traveled to the residence of Brandon OCallaghan, the former owner and pharmacist for Spring Valley Family Pharmacy, in Winfield, West Virginia on April 26, 2021.
Request for Final Agency Action, dated June 9, 2021 hereinafter, RFAA, Exhibit hereinafter, RFAAX 3 at 1. The DI stated that on that date, she personally handed Mr. OCallaghan a copy of the OSC. Id. The DI also stated that Mr. OCallaghan signed Form DEA12 Receipt for Cash or Other Items, which indicated that he received a copy of the OSC. Id. In her Declaration, the DI included a true and correct copy of the DEA12 that Mr.
OCallaghan signed. RFAAX 3, Appendix hereinafter, App. A.
The Government forwarded its RFAA, along with the evidentiary record, to this office on June 10, 2021. In its RFAA, the Government represents that Registrant has not submitted a timely request for a hearing in this matter. 1
RFAA, at 1.
The Government seeks to revoke the DEA COR of Registrant because Registrant lacks authority to handle controlled substances in the State of Ohio, the state where Registrant is registered with DEA. Id. The Government requests that the Administrator revoke Registrants DEA
registration. Id. at 5.
Based on the DIs Declaration, the Governments written representations, and my review of the record, I find that the Government accomplished service of the OSC on Registrant on April 26, 2021. I also find that more than thirty days have now passed since the Government accomplished service of the OSC. Further, based on the Governments written representations, I
find that neither Registrant, nor anyone purporting to represent the Registrant, requested a hearing, submitted a written statement while waiving Registrants 1 The Government included a second DI
Declaration, dated June 9, 2021, in its RFAA, which stated that DEA has not received any correspondence from Spring Valley Family Pharmacy concerning the OSC. RFAAX 4, at 2.

E:FRFM02JYN1.SGM

02JYN1